Citadel Advisors’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Citadel Advisors’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-109,200	Closed	-$76.3K	–	15664
2023 Q1	$76.3K	Sell	109,200 -41,600	-28%	-$38.3K	﹤0.01%	11625
2022 Q4	$136K	Buy	150,800 +124,100	+465%	+$360K	﹤0.01%	10760
2022 Q3	$160K	Buy	+26,700	New	+$151K	﹤0.01%	10640

Citadel Advisors's STSA Position: Q2 2023 in Review

Citadel Advisors sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 5,397 shares — an estimated $3.77K sold.

Citadel Advisors first reported a position in STSA in Q3 2019 and held it in 14 quarters. The position peaked at $29.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Citadel Advisors reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 5,397 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $3.77K.
Citadel Advisors first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 14 quarters.
Citadel Advisors's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $29.6M in Q2 2020.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.